EMERGENT BIOSOLUTIONS INC. (EBS) Operating Margin
- Operating margin · 12 months: Value -8.57%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -8.57% | Operating income / revenue. Period ending 2026-06-30. $-66.00M ÷ $770.20M × 100 ≈ -8.57% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -66.00M USD | Operating Income (Loss) |
| Revenue | 770.20M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 339.90M USD | Cost of Goods and Services Sold |
| Research and development | 45.30M USD | Research and Development Expense |
| Selling, general and administration | 181.20M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-66.00M | $770.20M | $339.90M | $45.30M | $181.20M | -8.57% |
| 2026-03-31 | $60.70M | $676.80M | $309.70M | $48.60M | $180.30M | 8.97% |
| 2025-12-31 | $100.10M | $742.90M | $326.20M | $53.20M | $186.10M | 13.47% |
| 2025-09-30 | $118.50M | $788.90M | (m) | $50.20M | $195.80M | 15.02% |
| 2025-06-30 | $106.50M | $851.60M | (m) | $50.50M | $233.50M | 12.51% |
| 2025-03-31 | $-98.60M | $965.40M | (m) | $70.70M | $275.70M | -10.21% |
| 2024-12-31 | $-108.70M | $1.04B | (m) | $70.70M | $308.00M | -10.42% |
| 2024-09-30 | $-143.00M | $1.13B | $748.40M | $91.00M | $336.90M | -12.71% |
| 2024-06-30 | $-449.60M | $1.10B | $802.60M | $92.50M | $346.30M | -40.79% |
| 2024-03-31 | $-539.00M | $1.19B | $697.10M | $85.80M | $351.80M | -45.47% |
| 2023-12-31 | $-726.40M | $1.05B | $705.40M | $111.40M | $368.40M | -69.23% |
| 2023-09-30 | $-737.90M | $1.10B | $740.80M | $129.00M | $372.10M | -66.91% |
| 2023-06-30 | $-548.10M | $1.07B | $713.70M | $163.40M | $366.30M | -51.05% |
| 2023-03-31 | $-327.20M | $978.50M | $692.90M | $187.20M | $356.00M | -33.44% |
| 2022-12-31 | $-172.70M | $1.12B | $693.70M | $193.00M | $340.30M | -15.41% |
| 2022-09-30 | $169.80M | $1.51B | (m) | $218.40M | $340.30M | 11.22% |
| 2022-06-30 | $177.10M | $1.60B | (m) | $228.80M | $342.20M | 11.05% |
| 2022-03-31 | $263.60M | $1.76B | (m) | $227.90M | $352.30M | 15.00% |
| 2021-12-31 | $352.60M | $1.79B | (m) | $234.00M | $348.40M | 19.67% |
| 2021-09-30 | $333.30M | $1.65B | (m) | $210.50M | $336.30M | 20.17% |
| 2021-06-30 | $429.30M | $1.71B | $644.40M | $245.30M | $329.70M | 25.12% |
| 2021-03-31 | $540.80M | $1.71B | $546.40M | $244.30M | $314.50M | 31.70% |
| 2020-12-31 | $433.80M | $1.56B | $524.00M | $234.50M | $303.30M | 27.89% |
| 2020-09-30 | $253.40M | $1.33B | $488.50M | $237.80M | $293.40M | 19.01% |
| 2020-06-30 | $262.90M | $1.26B | $447.50M | $206.80M | $282.80M | 20.88% |
| 2020-03-31 | $129.70M | $1.11B | $418.60M | $222.80M | $277.80M | 11.71% |
| 2019-12-31 | $114.10M | $1.11B | $433.50M | $226.20M | $273.50M | 10.32% |
| 2019-09-30 | $47.60M | $351.80M | $414.20M | $215.40M | $282.00M | 13.53% |
| 2019-06-30 | $-1.90M | $213.70M | $375.60M | $199.00M | $259.20M | -0.89% |
| 2019-03-31 | $72.10M | $190.60M | $359.80M | $159.80M | $227.90M | 37.83% |
| 2018-12-31 | $89.80M | $782.40M | $322.30M | $142.80M | $202.50M | 11.48% |
| 2018-09-30 | $131.68M | $705.48M | (m) | $119.30M | $163.79M | 18.67% |
| 2018-06-30 | $158.14M | $681.26M | (m) | $104.95M | $156.19M | 23.21% |
| 2018-03-31 | $99.89M | $561.83M | (m) | $105.96M | $148.55M | 17.78% |
| 2017-12-31 | $124.28M | $560.87M | (m) | $97.38M | $143.50M | 22.16% |
| 2017-09-30 | $122.14M | $518.73M | (m) | $96.00M | $136.88M | 23.55% |
| 2017-06-30 | $109.85M | $512.21M | (m) | $100.53M | $143.06M | 21.45% |
| 2017-03-31 | $99.28M | (m) | (m) | $102.67M | $147.12M | (m) |
| 2016-12-31 | $105.52M | $488.78M | (m) | $108.29M | $143.69M | 21.59% |
| 2016-09-30 | $74.26M | (m) | (m) | $141.34M | $170.52M | (m) |
| 2016-06-30 | $97.84M | $545.53M | (m) | $143.85M | $161.44M | 17.93% |
| 2016-03-31 | $132.91M | $570.16M | (m) | $149.45M | $153.75M | 23.31% |
| 2015-12-31 | $96.04M | $522.79M | (m) | $154.00M | $148.46M | 18.37% |
| 2015-09-30 | $90.77M | $502.66M | (m) | $160.48M | $134.41M | 18.06% |
| 2015-06-30 | $68.79M | $475.67M | (m) | $162.81M | $133.14M | 14.46% |
| 2015-03-31 | $55.20M | $459.89M | (m) | $159.28M | $127.25M | 12.00% |
| 2014-12-31 | $58.06M | $450.14M | (m) | $150.83M | $122.84M | 12.90% |
| 2014-09-30 | $36.73M | $400.27M | (m) | $141.86M | $116.33M | 9.18% |
| 2014-06-30 | $23.84M | $351.42M | (m) | $126.59M | $108.00M | 6.79% |
| 2014-03-31 | $30.69M | $323.53M | (m) | $119.47M | $97.94M | 9.49% |
| 2013-12-31 | $42.80M | $312.75M | (m) | $119.93M | $87.88M | 13.69% |
| 2013-09-30 | $43.54M | $309.24M | (m) | $125.88M | $81.96M | 14.08% |
| 2013-06-30 | $35.21M | $286.73M | (m) | $124.34M | $79.16M | 12.28% |
| 2013-03-31 | $29.16M | $274.68M | (m) | $124.70M | $76.55M | 10.61% |
| 2012-12-31 | $29.97M | $281.89M | (m) | $120.23M | $76.02M | 10.63% |
| 2012-09-30 | $51.92M | $295.23M | (m) | $113.66M | $74.80M | 17.59% |
| 2012-06-30 | $43.51M | $287.40M | (m) | $115.48M | $73.07M | 15.14% |
| 2012-03-31 | $55.07M | $305.16M | (m) | $116.32M | $75.56M | 18.05% |
| 2011-12-31 | $32.10M | $273.38M | (m) | $124.83M | $74.28M | 11.74% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $73.56M | $286.17M | (m) | $89.30M | $76.20M | 25.70% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $40.15M | $234.79M | (m) | $74.59M | $73.79M | 17.10% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |